Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I.

Post time 3 day(s) ago

journal：Journal of Clinical Oncology

Authors：Herui Yao; Min Yan; Zhongsheng Tong; Xinhong Wu; Min-Hee Ryu; John J. Park; Jee Hyun Kim; Yahua Zhong; Yiming Zhao; Mark Voskoboynik; Yongmei Yin; Kan Liu; Andreas Kaubisch; Caigang Liu; Jian Zhang; Shouman Wang; Seock-Ah Im; Vinod Ganju; Minal Barve; Hui Li; Changsheng Ye; Amitesh C. Roy; Li-Yuan Bai; Chia-Jui Yen; Shanzhi Gu; Yung-Chang Lin; Lingying Wu; Lequn Bao; Kaijing Zhao; Yu Shen; Shangyi Rong; Xiaoyu Zhu; Erwei Song

Published date：--

DOI：10.1200/jco.23.02044

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.23.02044

Article link：http://dx.doi.org/10.1200/jco.23.02044

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time Yesterday 14:52

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Other] Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I.

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I. Copy

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I.